Welcome to our dedicated page for Acadia Healthcare Company SEC filings (Ticker: ACHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Acadia Healthcare Company's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Acadia Healthcare Company's regulatory disclosures and financial reporting.
WAUD REEVE B reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director Reeve B. Waud reported equity compensation in the form of common stock. On May 6, 2026, he received two stock awards of 9,576 shares and 6,331 shares at a price of $0.00 per share, including shares received in lieu of his 2026 annual cash director retainer. The shares will vest over a three-year period in equal yearly installments beginning May 6, 2027. Following these awards, Waud directly holds 75,859 shares. He is also reported as indirectly holding 653,015 shares through various trusts and Waud Capital Partners, L.L.C., while expressly disclaiming beneficial ownership except to the extent of his pecuniary interest.
Acadia Healthcare Company, Inc. director Bissell E. Perot reported compensation-related stock awards rather than open‑market trades. On May 6, 2026, he acquired 5,500 shares of common stock at no cash cost as a grant that will vest over three years in equal annual installments beginning May 6, 2027.
He also acquired an additional 6,331 shares of common stock at no cash cost, reflecting his election to receive his 2026 annual cash retainer as a director in shares instead of cash. Both transactions are classified as grants or awards, not market purchases or sales.
Acadia Healthcare Company, Inc. executive Brian Farley, EVP, CLAO and Secretary, reported a routine tax-related share disposition. On this Form 4, 5,063 shares of common stock were withheld at $27.69 per share to cover tax obligations, rather than sold on the open market. After this tax-withholding disposition, Farley directly holds 139,122 shares of Acadia Healthcare common stock.
Acadia Healthcare Company, Inc. held its annual meeting of stockholders on May 6, 2026. Stockholders elected three Class III directors—Daniel J. Cancelmi, Michael J. Fucci and Patrice A. Harris, M.D., M.A.—each receiving over 73.5 million votes in favor.
Investors also approved a second amendment to the Amended and Restated Incentive Compensation Plan, with 80,102,444 votes for and 779,641 against. On a non-binding advisory basis, stockholders approved compensation of the Named Executive Officers, with 60,889,503 votes for and 19,942,924 against.
Finally, stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 83,941,435 votes for and 1,947,371 against.
Acadia Healthcare Company, Inc. executive Brian Farley, EVP, CLAO and Secretary, reported an equity award of common stock. He acquired 37,510 shares of common stock at $0.00 per share as a grant classified as a “grant, award, or other acquisition.”
These shares will vest over three years in equal yearly installments beginning on April 10, 2027, so the award is subject to a multi‑year service-based schedule. Following this grant, Farley directly holds 144,185 shares of Acadia Healthcare common stock. This is a compensation-related grant rather than an open-market trade.
Acadia Healthcare reported first-quarter 2026 revenue of $828.8 million, up 7.6% from $770.5 million a year earlier, driven by higher same-facility volumes and pricing. Medicaid represented 60.7% of revenue, reflecting the company’s focus on publicly funded behavioral health services.
Net income attributable to Acadia fell to $4.1 million, or $0.05 per diluted share, compared with $8.4 million and $0.09 a year earlier, as higher interest expense and legal-related costs weighed on results. Legal settlements expense rose to $13.8 million, mainly from an agreement in principle to resolve the Sandoval wrongful death litigation.
Operating cash flow strengthened to $61.5 million from $11.5 million, helped by working-capital improvements, while cash ended the quarter at $158.5 million. Total debt stood at about $2.53 billion, including term loans and three series of senior notes. The company operates 275 facilities with roughly 12,400 beds and continues to invest in growth through new beds, joint ventures and de novo facilities.
Acadia Healthcare Company, Inc. reported first quarter 2026 revenue of $828.8 million, up 7.6% from $770.5 million a year earlier, driven by 7.3% same-facility revenue growth and higher patient volumes and pricing. Acute inpatient revenue rose 14%, while residential and comprehensive treatment facilities posted modest gains and specialty treatment facilities declined.
Adjusted EBITDA increased to $144.2 million from $134.2 million, but reported diluted EPS fell to $0.05 from $0.09 and adjusted EPS declined to $0.37 from $0.40 as interest expense and legal settlement costs rose. The company added 82 new beds in the quarter, ended with $158.5 million in cash, and reported a 3.9x net leverage ratio. Management raised full-year 2026 guidance, targeting revenue of $3.37–$3.45 billion, adjusted EBITDA of $580–$615 million, and adjusted EPS of $1.35–$1.60.
Acadia Healthcare Co Inc reports a Schedule 13G showing Vanguard Capital Management beneficially owns 4,838,637 shares of Common Stock, representing 5.25% of the class. The filing states Vanguard has sole dispositive power over 4,838,637 shares and sole voting power over 683,836 shares. The filing is signed by Ashley Grim on 04/29/2026.
Acadia Healthcare Co Inc reports a Schedule 13G disclosure showing Vanguard Portfolio Management beneficially owns 5,079,563 shares of Common Stock, equal to 5.51% of the class. The filing states Vanguard Portfolio Management has sole dispositive power over 5,079,563 shares and sole voting power over 18,125 shares. The disclosure is signed by Ashley Grim on 04/28/2026 and cites the portfolio management and affiliated Vanguard entities described in the release.
Acadia Healthcare Company, Inc. reported a planned Chief Financial Officer transition and reaffirmed its first quarter and full-year 2026 financial guidance. Todd Young will resign as CFO effective April 30, 2026 and will participate in the April 30 earnings call.
The Board appointed former CFO David M. Duckworth as Interim CFO and principal financial officer effective May 1, 2026. His employment agreement runs initially through May 1, 2027, with a base salary of $100,000 per month and eligibility for a $125,000 quarterly cash bonus, plus defined severance protections.
The company highlighted Duckworth’s long prior tenure as CFO from 2012 to 2023 and reiterated that its previously issued 2026 outlook remains in place. Acadia also described customary confidentiality, non-competition and indemnification arrangements associated with his role.